Physician profile
Ravikumar Bhalavat
NPI 1447406624
$1,229.80
in general payments reported to CMS, 2019-2025
16 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $14.61 · 2021: $13.42 · 2022: $279 · 2023: $152 · 2024: $264 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $784.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $352.21 | 2022-2025 | Vraylar |
| Alkermes, INC. | $174.46 | 2019-2024 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $114.59 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $84.25 | 2022-2025 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $76.87 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $69.72 | 2019-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $66.35 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $66.06 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.37 | 2022-2024 | Caplyta |
| Supernus Pharmaceuticals, INC. | $46.66 | 2021-2022 | |
| Corium, LLC | $33.89 | 2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $27.65 | 2024 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $15.79 | 2025 | Uzedy |
| Axsome Therapeutics, INC. | $15.07 | 2023 | Auvelity |
| Neuronetics, INC. | $14.61 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $14.25 | 2025 | Contrave, Onzetra Xsail |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravikumar Bhalavat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.